EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)ÄquivalenzstudieRandomisierte kontrollierte Studie

Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects

Zhengzhi Liu, Jinling Xue, Qiaohuan Deng, Yanli Wang, Lixiu Zhang, Lang Liu, Nan Xiao, Tianying Chang, Yingzi Cui, Yang Cheng, Guangwen Liu, Wanhua Wang und 7 weitere

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024

DOI: 10.1007/s00210-024-03055-1 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Zhengzhi Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China. Hauptthemen laut MEDLINE: Antipsychotic Agents, Drugs, Generic, Lurasidone Hydrochloride, Therapeutic Equivalency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsDrugs, GenericLurasidone HydrochlorideTherapeutic EquivalencyAdultFemaleHumansMaleYoung AdultArea Under CurveCross-Over StudiesEast Asian PeopleHealthy Volunteers

Stichwörter der Autor:innen

AntipsychoticBioequivalenceLurasidonePharmacokineticsTolerability

Substanzen

Antipsychotic AgentsDrugs, GenericLurasidone Hydrochloride

Autor:innen und Institutionen

  • Phase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
  • Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.
  • Lung Disease Center, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
  • The Clinical Trial Quality Control Center, Ansiterui Medical Technology Consulting Co., Ltd., Changchun, China.
  • Center for Pathogen Biology and Infectious Diseases, Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, The First Hospital of Jilin University, Changchun, China.
  • Northeast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. zeyu781022@163.com.

Zitieren

APA

Liu, Z., Xue, J., Deng, Q., Wang, Y., Zhang, L., Liu, L., Xiao, N., Chang, T., Cui, Y., Cheng, Y., Liu, G., Wang, W., Zhou, Y., Yang, W., Qu, X., Chen, J., Zhao, Y., Wang, Z., & Yang, H. (2024). Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03055-1

Vancouver

Liu Z, Xue J, Deng Q, Wang Y, Zhang L, Liu L, et al. Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-03055-1

BibTeX
@article{Liu2024,
  author = {Liu, Zhengzhi and Xue, Jinling and Deng, Qiaohuan and Wang, Yanli and Zhang, Lixiu and Liu, Lang and Xiao, Nan and Chang, Tianying and Cui, Yingzi and Cheng, Yang and Liu, Guangwen and Wang, Wanhua and Zhou, Yannan and Yang, Wei and Qu, Xinyao and Chen, Jiahui and Zhao, Yicheng and Wang, Zeyu and Yang, Haimiao},
  title = {Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  doi = {10.1007/s00210-024-03055-1}
}
Kostenlos starten →